Esperion
is a Michigan-based pharmaceutical company that researches and develops oral therapies for the treatment of cardiovascular and cardiometabolic diseases... Read moreEsperion
is a Michigan-based pharmaceutical company that researches and develops oral therapies for the treatment of cardiovascular and cardiometabolic diseases... Read more
1998
PublicAcquired by ArchiMed SASNASDAQESPR
News
Jul 15, 2026
Pulse2.0
Esperion: ARCHIMED Successfully Completes Take-Private of Esperion in $1.1 Billion Deal
May 26, 2026
GlobalNewswire
Press Release: Esperion : Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
May 15, 2026
GlobeNewswire
Esperion: Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
May 14, 2026
Zacks
Esperion: ESPR Stock Surges 44% in a Month
May 13, 2026
GlobeNewswire
Press Release: Esperion : Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
May 09, 2026
Owler
Esperion Therapeutics, Inc.: Esperion's revenue changed from $403.13M in Dec 2025 to $418.24M in Mar 2026
May 04, 2026
Benzinga
Esperion: What's Going On With Esperion Therapeutics Stock On Monday?
May 01, 2026
GlobalNewswire
Press Release: Esperion : $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)
May 01, 2026
Benzinga
Esperion: Esperion to be Acquired by ARCHIMED
May 01, 2026
PR Newswire
Press Release: Esperion : Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Esperion Competitors
1
2
3
4
5
6
7
8
9
10